However, additional studies conducted in larger and independent cohorts will be required to further validate these findings including thoroughly explore potential sexual dimorphism since it affects both IGFBP-2 and NAFLD (14, 15). This evidence concerns the gene IGFBP2 and metabolic dysfunction-associated steatotic liver disease.